M Markman

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi "Therapeutic intent" in phase 1 oncology trials: a justifiable objective
    Maurie Markman
    The University of Texas M. D. Anderson Cancer Center, Mail Box 121, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Intern Med 166:1446-8. 2006
  2. ncbi Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103
    Maurie Markman
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Exp Ther Oncol 4:131-6. 2004
  3. ncbi Profile of ovarian cancer patients seeking information from a web-based decision support program
    Maurie Markman
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Womens Health (Larchmt) 15:312-8. 2006
  4. ncbi Unresolved issues in the chemotherapeutic management of gynecologic malignancies
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S33-8. 2006
  5. ncbi Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:849-53. 2006
  6. ncbi Chemotherapy-induced peripheral neuropathy: underreported and underappreciated
    Maurie Markman
    University of Texas M D Anderson Cancer Center Mail Box 121, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Pain Headache Rep 10:275-8. 2006
  7. ncbi Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
    Maurie Markman
    University of Texas MD Anderson Cancer Center, Mail Box 121, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Expert Opin Pharmacother 7:1469-74. 2006
  8. ncbi The "new" era of oral antineoplastic drug therapy: revisiting "old" concerns
    Maurie Markman
    University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:317-8. 2006
  9. ncbi Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer
    Maurie Markman
    The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S3-7. 2006
  10. ncbi New, expanded, and modified use of approved antineoplastic agents in ovarian cancer
    Maurie Markman
    Department of Gynecologic Medical Oncology, University of Texas M D Anderson Cancer Center Mail Box 121, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 12:186-90. 2007

Detail Information

Publications123 found, 100 shown here

  1. ncbi "Therapeutic intent" in phase 1 oncology trials: a justifiable objective
    Maurie Markman
    The University of Texas M. D. Anderson Cancer Center, Mail Box 121, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Arch Intern Med 166:1446-8. 2006
  2. ncbi Improving the toxicity profile of chemotherapy for advanced ovarian cancer: a potential role for CT-2103
    Maurie Markman
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Exp Ther Oncol 4:131-6. 2004
    ..Ongoing trials employing this agent will focus on extending survival, optimizing quality of life, and defining a possible role for CT-2103 in the standard management of advanced ovarian cancer...
  3. ncbi Profile of ovarian cancer patients seeking information from a web-based decision support program
    Maurie Markman
    University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    J Womens Health (Larchmt) 15:312-8. 2006
    ..There is limited information available regarding the characteristics of patients who elect to gather and share information about their malignancy on the Internet...
  4. ncbi Unresolved issues in the chemotherapeutic management of gynecologic malignancies
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S33-8. 2006
    ....
  5. ncbi Influence of tumor type, disease status, and patient age on self-reported interest regarding participation in cancer clinical trials
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:849-53. 2006
    ..Particularly notable was the reduced desire to gather such information among the very elderly, and the increased interest by patients with the most serious cancer-related conditions...
  6. ncbi Chemotherapy-induced peripheral neuropathy: underreported and underappreciated
    Maurie Markman
    University of Texas M D Anderson Cancer Center Mail Box 121, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Pain Headache Rep 10:275-8. 2006
    ....
  7. ncbi Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
    Maurie Markman
    University of Texas MD Anderson Cancer Center, Mail Box 121, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Expert Opin Pharmacother 7:1469-74. 2006
    ..In recurrent and platinum-resistant ovarian cancer, single-agent pegylated liposomal doxorubicin has assumed an important role in routine patient management...
  8. ncbi The "new" era of oral antineoplastic drug therapy: revisiting "old" concerns
    Maurie Markman
    University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 8:317-8. 2006
  9. ncbi Clinical efficacy supporting the role of intraperitoneal drug delivery in the primary chemotherapeutic management of small-volume residual advanced ovarian cancer
    Maurie Markman
    The University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S3-7. 2006
    ....
  10. ncbi New, expanded, and modified use of approved antineoplastic agents in ovarian cancer
    Maurie Markman
    Department of Gynecologic Medical Oncology, University of Texas M D Anderson Cancer Center Mail Box 121, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 12:186-90. 2007
    ..g., gemcitabine, docetaxel, etoposide, irinotecan, vinorelbine, and bevacizumab). It can be anticipated that future studies involving novel approved agents will further expand the oncologist's weapons against ovarian cancer...
  11. ncbi Informing prospective research subjects of the influence of regulatory requirements for drug approval on the design of clinical trials in oncology
    Maurie Markman
    Department of Gynecologic Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1003-6. 2007
  12. ncbi The dangers of "cross-trial" and "cross-retrospective experience" comparisons: examples employing data in the peer-reviewed ovarian cancer literature
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 109:1929-32. 2007
  13. ncbi Significance of early changes in the serum CA-125 antigen level on overall survival in advanced ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 103:195-8. 2006
    ..The relationship between survival and early changes in the serum level of the CA-125 antigen in patients with advanced ovarian cancer remains poorly defined...
  14. ncbi Pretreatment CA-125 and risk of relapse in advanced ovarian cancer
    Maurie Markman
    M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 24:1454-8. 2006
    ....
  15. ncbi Clinical features of American versus non-American gynecologic cancer patients requesting information from a proprietary web-based decision-support program
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Cancer Res Clin Oncol 132:439-43. 2006
    ....
  16. ncbi Liposomal anthracycline treatment for ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:91-105. 2004
    ..Proper dosing and monitoring may further enhance tolerability while preserving the efficacy of this versatile agent for ovarian cancer...
  17. ncbi Hormonal therapy of endometrial cancer
    Maurie Markman
    M D Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Houston, TX 77025, USA
    Eur J Cancer 41:673-5. 2005
    ..Hormonal therapy of advanced or recurrent endometrial cancer is a well-established therapeutic option. Patients most likely to respond have lower grade tumours and possess progesterone receptors on the surface of their cancer cells...
  18. ncbi Chemotherapy-induced peripheral neuropathy: an increasing concern for oncologists
    Maurie Markman
    University of Texas M.D. Anderson Cancer Center, Box 121, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 7:159-60. 2005
  19. ncbi Management of ovarian cancer. An impressive history of improvement in survival and quality of life
    Maurie Markman
    The University of Texas, M D Anderson Cancer Center, Houston 77005, USA
    Oncology (Williston Park) 20:347-54; discussion 354, 357-8, 364 passim. 2006
    ..This paper will discuss that historical background, describe the increasingly favorable impact of evolving treatment paradigms in ovarian cancer, and note future directions for clinical research in this complex disease process...
  20. ncbi Supportive care
    Maurie Markman
    M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Chemother Biol Response Modif 22:677-86. 2005
  21. ncbi Topotecan as second-line therapy for ovarian cancer: dosage versus toxicity
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 10:695-7. 2005
    ..25 mg/m(2) per day x 5 days) will essentially eliminate concern for the development of severe clinically relevant marrow toxicity is uncertain, but the risk will certainly be substantially reduced...
  22. ncbi An examination of characteristics of lung and colon cancer patients participating in a web-based decision support program. Internet-based decision support programs
    Maurie Markman
    Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Oncology 69:311-6. 2005
    ..Little is known about the characteristics of cancer patients who employ the Internet as a technique to gather information to assist them in their management...
  23. ncbi Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study
    Maurie Markman
    University of Texas, M D Anderson, 1515 Holcombe Blvd, Mail Box 121, Houston, TX 77030 4009, USA
    Gynecol Oncol 101:436-40. 2006
    ..To evaluate the activity of single agent weekly paclitaxel in patients with both platinum and paclitaxel (delivered every 3 weeks)-resistant ovarian cancer...
  24. ncbi Reflections on ethical concerns arising from the incorporation of results of randomized trials of antineoplastic therapy into routine clinical practice
    Maurie Markman
    University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Invest 23:735-40. 2005
    ..This decision-making process has the potential to result in serious ethical dilemmas...
  25. ncbi Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment
    Maurie Markman
    The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:988-94. 2006
  26. ncbi Providing research participants with findings from completed cancer-related clinical trials: not quite as simple as it sounds
    Maurie Markman
    Office of Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Cancer 106:1421-4. 2006
  27. ncbi Use of progression-free survival as a valid endpoint in phase II cancer clinical trials
    Maurie Markman
    University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA
    Curr Oncol Rep 9:159-60. 2007
  28. ncbi Justification for separate consideration of two broad categories of cancer patient use of complementary medicine
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Soc Integr Oncol 5:50-2. 2007
    ..This article provides the rationale for this statement and the potential utility of this approach...
  29. ncbi The promise and perils of 'targeted therapy' of advanced ovarian cancer
    Maurie Markman
    University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology 74:1-6. 2008
    ..It is anticipated that future trials of 'targeted' therapy in ovarian cancer will focus on molecular targets of documented relevance in the malignancy...
  30. ncbi Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies
    Maurie Markman
    Department of Gynecological Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Trends Pharmacol Sci 29:515-9. 2008
    ..Although 'targeted therapeutic approaches' are currently being explored in this disease, with the important exception of anti-angiogeneic agents, to date, limited biological and clinical activity have been demonstrated...
  31. ncbi The myth of measurable disease in ovarian cancer: revisited
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 27:11-2. 2009
    ..g., CA-125), which can more adequately define changes in "tumor volume" associated with small nonvisualized macroscopic and diffuse microscopic cancer...
  32. ncbi An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer
    Maurie Markman
    From the Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer J 15:105-9. 2009
    ..Future research efforts are mandated to develop regimens which improve the toxicity profile of this novel method of treatment while maintaining the documented enhanced efficacy of the approach...
  33. ncbi Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncol
    Maurie Markman
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77005, USA
    Gynecol Oncol 114:195-8. 2009
    ..At study closure, it was too early to assess the impact on overall survival...
  34. ncbi Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77005, USA
    J Womens Health (Larchmt) 18:827-9. 2009
    ..There are limited data available in the medical literature concerning the issue of the depth of information presented on cancer-related Internet-based dealing with disease management...
  35. ncbi Antiangiogenic drugs in ovarian cancer
    Maurie Markman
    The University of Texas MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, Houston, Texas 77005, USA
    Expert Opin Pharmacother 10:2269-77. 2009
    ..There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer...
  36. ncbi Point: Intraperitoneal chemotherapy in the management of ovarian cancer
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Natl Compr Canc Netw 2:549-54. 2004
    ..Further exploration of this unique management strategy is indicated to develop an optimal approach that maintains the demonstrated enhanced efficacy while reducing the toxicity (principally because of cisplatin) of treatment...
  37. ncbi PET/CT scans in ovarian cancer: prognostic versus predictive utility?
    M Markman
    Department of Gynecologic Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX, USA
    Minerva Med 100:415-20. 2009
    ....
  38. ncbi Optimal management of recurrent ovarian cancer
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Int J Gynecol Cancer 19:S40-3. 2009
    ....
  39. ncbi Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial
    Maurie Markman
    University of Texas, M D Anderson Cancer Center, Unit 1435, Houston, TX 77030, USA
    Gynecol Oncol 116:323-5. 2010
    ....
  40. ncbi Assigning a cause for a particular outcome in oncology: a serious note of caution
    Maurie Markman
    Clinical Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:668-70. 2008
  41. ncbi Pharmaceutical management of ovarian cancer : current status
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Drugs 68:771-89. 2008
    ..Reasonable goals of therapy in women with recurrent or resistant ovarian cancer are to improve overall survival, reduce the severity (and delay the occurrence) of symptoms and optimize overall quality of life...
  42. ncbi Maintenance chemotherapy in advanced ovarian cancer: the US experience
    M Markman
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 18:40-3. 2008
    ..An ongoing Gynecologic Oncology Group trial in the United States will hopefully provide a definitive answer to the question of the impact of this novel strategy on outcome in ovarian cancer...
  43. ncbi Human papillomavirus vaccines to prevent cervical cancer
    Maurie Markman
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Lancet 369:1837-9. 2007
  44. ncbi An examination of the influence of patient race and ethnicity on expressed interest in learning about cancer clinical trials
    Maurie Markman
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box 121, Houston, TX 77030, USA
    J Cancer Res Clin Oncol 134:115-8. 2008
    ..An important issue is the fundamental interest, or lack thereof, of these specific patient populations in actually considering study participation...
  45. ncbi Current status of intraperitoneal antineoplastic drug delivery
    M Markman
    University of Texas M D Anderson Cancer Center, Houston 77005, USA
    Cancer Treat Res 134:153-69. 2007
  46. ncbi Differences between a drug regimen employed in early phase 1 trials and the subsequent use of the agent in routine oncologic practice: a note of caution
    Maurie Markman
    Clinical Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1644-7. 2007
  47. ncbi The role of independent review to insure ethical quality-improvement activities in oncology: a commentary on the national debate regarding the distinction between quality-improvement initiatives and clinical research
    Maurie Markman
    Office of Clinical Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:2597-600. 2007
  48. ncbi Prohibition against competing cancer clinical trials: a counter argument
    Maurie Markman
    Clinical Research, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:455-7. 2008
  49. ncbi "Conflict-of-interest" and participation in IRB deliberations: an alternative perspective
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 26:115-7. 2008
    ..Management of real or perceived conflict must include full disclosure, but exclusion of such individuals from the deliberative process may result in undesirable consequences...
  50. ncbi Taxanes in the management of gynecologic malignancies
    Maurie Markman
    The University of Texas, MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Expert Rev Anticancer Ther 8:219-26. 2008
    ....
  51. ncbi An ethical argument in support of interactions between developing world countries and pharmaceutical/biotechnology companies involved in oncology drug development
    Maurie Markman
    Clinical Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 112:1871-3. 2008
  52. ncbi Strategies to examine new compounds for intraperitoneal use in ovarian cancer
    M Markman
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 18:33-5. 2008
    ....
  53. ncbi What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?
    M Markman
    The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Int J Gynecol Cancer 18:36-9. 2008
    ..Based on very reasonable extrapolations from existing evidence-based data, a number of possible "options" can be proposed that use the intraperitoneal route for delivery of chemotherapy in this clinical setting...
  54. ncbi Maintenance chemotherapy: an evolving and increasingly acceptable strategy in cancer management
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Curr Oncol Rep 12:349-51. 2010
    ..This commentary briefly reviews data from several of these reports...
  55. ncbi Experience with platinum-based and high-dose chemotherapy in patients with gestational trophoblastic disease: possible implications for future management
    Maurie Markman
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box 121, Houston, TX 77030 4009, USA
    J Cancer Res Clin Oncol 130:383-7. 2004
    ..Despite the similarities between the chemotherapeutic management of advanced gestational trophoblastic disease (GTD) and ovarian germ cell tumors, important differences exist between the malignancies, particularly in the use of cisplatin...
  56. ncbi Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials
    Maurie Markman
    Department of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 93:699-701. 2004
    ..There are very limited data in the oncology literature regarding the survival of women with both platinum and taxane-refractory ovarian cancer...
  57. ncbi Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design
    Maurie Markman
    From the Department of Hematology Medical Oncology, Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 22:3120-5. 2004
    ..Limited information is available regarding the influence of the duration of a prior response on the length of a subsequent response to platinum chemotherapy in recurrent ovarian cancer...
  58. ncbi Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn
    Maurie Markman
    Department of Obstetrics and Gynecology, M D Anderson Cancer Center, 1515 Holcombe Boulevard, 43, Houston, TX 77030 4009, USA
    Gynecol Oncol 94:578-80. 2004
    ..Palmar-plantar erythrodysesthesia (PPE) is a potentially serious toxicity of a number of cytotoxic chemotherapeutic agents, including liposomal doxorubicin. Activities that may increase the risk of this toxicity should be avoided...
  59. ncbi Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers
    Maurie Markman
    University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Cancer Res Clin Oncol 130:741-4. 2004
    ..There are limited data available in the oncology literature regarding the risk of thrombocytopenia associated with carboplatin-based second-line treatment of ovarian cancer, outside the setting of patients participating in clinical trials...
  60. ncbi A rationale for neoadjuvant systemic treatment followed by surgical assessment and intraperitoneal chemotherapy in patients presenting with non-surgically resectable ovarian or primary peritoneal cancers
    Maurie Markman
    Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
    J Cancer Res Clin Oncol 131:26-30. 2005
    ..Optimal management of patients with advanced ovarian or primary peritoneal cancers who have received, and achieved an excellent response to, neoadjuvant chemotherapy remains undefined...
  61. ncbi Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions
    Maurie Markman
    Department of Gynecologic Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Rev Recent Clin Trials 2:169-73. 2007
    ....
  62. ncbi Phase 2 trial of prolonged administration of oral topotecan in platinum/taxane-refractory ovarian, fallopian tube, and primary peritoneal cancers
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 95:109-13. 2004
    ..The availability of oral topotecan permits the exploration of the clinical utility of prolonged treatment programs employing this drug...
  63. ncbi Progress in the management of gynecologic cancer: consensus summary statement
    Stephen A Cannistra
    Department of Gynecologic Medical Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Brigham and Women's Hospital, Dana-Farber Cancer Institute, and Massachusetts General Hospital, Boston, USA
    J Clin Oncol 21:129s-132s. 2003
  64. ncbi Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, Department of Obstetrics and Gynecology, Cleveland Clinic Foundation, A81, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 104:114-9. 2007
    ....
  65. ncbi Optimizing primary chemotherapy in ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology R 35, Cleveland Clinic Cancer Center, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Hematol Oncol Clin North Am 17:957-68, viii. 2003
    ....
  66. ncbi Phase 2 trial of single agent docetaxel in platinum and paclitaxel-refractory ovarian cancer, fallopian tube cancer, and primary carcinoma of the peritoneum
    Maurie Markman
    Departments of Hematology Medical Oncology and Gynecology Obstetrics, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 91:573-6. 2003
    ..We wished to evaluate the biological and clinical activity of docetaxel in a patient population with well-characterized platinum and paclitaxel-refractory ovarian cancer...
  67. ncbi Paclitaxel in cancer therapy
    Tarek M Mekhail
    Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Expert Opin Pharmacother 3:755-66. 2002
    ..Paclitaxel is also active against AIDS-associated Kaposi's sarcoma...
  68. ncbi Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial
    Maurie Markman
    The Cleveland Clinic Foundation, OH 44195, USA
    J Clin Oncol 21:2460-5. 2003
    ....
  69. ncbi Ethical conflict in providing informed consent for clinical trials: a problematic example from the gynecologic cancer research community
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Oncologist 9:3-7. 2004
    ....
  70. ncbi Informing patients with cancer of "new findings" that may influence their willingness to participate in research studies
    Maurie Markman
    Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Cancer 98:885-7. 2003
  71. ncbi Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study
    Howard D Homesley
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brody School of Medicine, Greenville, NC, USA
    J Clin Oncol 25:526-31. 2007
    ..To determine if paclitaxel added to ifosfamide as first-line treatment for advanced uterine carcinosarcoma (CS) improves overall survival (OS), progression-free survival (PFS), response, and toxicity...
  72. ncbi Intraperitoneal antineoplastic drug delivery: rationale and results
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, and the Department of Hematology and Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA
    Lancet Oncol 4:277-83. 2003
    ....
  73. ncbi Phase II trial of single agent carboplatin followed by dose-intense paclitaxel, followed by maintenance paclitaxel therapy in stage IV ovarian, fallopian tube, and peritoneal cancers: a Southwest Oncology Group trial
    Maurie Markman
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 88:282-8. 2003
    ....
  74. ncbi The management of recurrent ovarian cancer
    Ronald M Bukowski
    The Cleveland Clinic Foundation Taussig Cancer Center, Cleveland Clinic Foundation Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, USA
    Semin Oncol 34:S1-15. 2007
  75. ncbi Effectiveness of serotonin-receptor antagonist antiemetic therapy over successive courses of carboplatin-based chemotherapy
    Margaret R Markman
    The Cleveland Clinic Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 85:435-7. 2002
    ....
  76. ncbi Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center, Cleveland, OH 44195, USA
    J Clin Oncol 20:2365-9. 2002
    ..We wished to critically examine the level of activity of weekly paclitaxel in a patient population with well-characterized platinum/paclitaxel-resistant (3-week schedule) ovarian cancer...
  77. ncbi Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer
    Maurie Markman
    The Cleveland Clinic Taussig Cancer Center, Department of Gynecology Obstetrics, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 90:593-6. 2003
    ..We wished to further define the level of activity of gemcitabine in women with well-characterized platinum/taxane refractory disease...
  78. ncbi Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma
    Chad M Michener
    Departments of Obstetrics Gynecology and Hematology Medical Oncology, The Cleveland Clinic Foundation, 9500, Euclid Avenue, Desk A81, Cleveland, OH, 44195, USA
    J Cancer Res Clin Oncol 131:581-4. 2005
    ..To evaluate the efficacy and safety of the combination of carboplatin plus paclitaxel in patients with advanced, metastatic and recurrent endometrial cancer...
  79. ncbi What must research subjects be told regarding the results of completed randomized trials?
    Maurie Markman
    MD Anderson Cancer Center, Houston, Texas, USA
    IRB 26:8-10. 2004
  80. ncbi Can we do a better job preventing clinically-relevant peripheral neuropathy resulting from carboplatin/paclitaxel chemotherapy?
    Maurie Markman
    The Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Cancer Invest 22:471-3. 2004
    ....
  81. ncbi Improved tolerance of primary chemotherapy with reduced-dose carboplatin and paclitaxel in elderly ovarian cancer patients
    Amanda Nickles Fader
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Gynecol Oncol 109:33-8. 2008
    ..Elderly cancer patients are less likely to tolerate chemotherapy. We sought to compare the toxicity profiles and outcomes of elderly ovarian cancer patients treated with standard versus reduced-dose i.v. carboplatin/paclitaxel...
  82. ncbi Second-line treatment of ovarian cancer with single-agent gemcitabine
    Maurie Markman
    Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Semin Oncol 29:9-10. 2002
    ....
  83. ncbi Phase 2 trial of carboplatin plus tamoxifen in platinum-resistant ovarian cancer and primary carcinoma of the peritoneum
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 94:404-8. 2004
    ..We wished to confirm or refute this observation in a patient population with well-characterized platinum-resistant disease...
  84. ncbi Managing taxane toxicities
    Maurie Markman
    Department of Hematology Medical Oncology R35, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Support Care Cancer 11:144-7. 2003
    ..g., for hypersensitivity reactions, bone marrow suppression) the taxanes have a favorable side effect profile, and it is currently uncommon for treatment to be discontinued because of the development of excessive toxicity...
  85. ncbi Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Group study
    Peter G Rose
    Division of Gynecologic Oncology, Case Western Reserve University, and MetroHealth Medical Center, Cleveland, OH, USA
    Gynecol Oncol 102:236-9. 2006
    ..A phase I study was conducted in previously treated ovarian or peritoneal carcinoma to determine the tolerability (maximum number of days) of sequential oral topotecan and oral etoposide...
  86. ncbi Role of intraperitoneal chemotherapy in the front-line setting
    Maurie Markman
    Cleveland Clinic Taussig Cancer Center and the Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    J Clin Oncol 21:145s-148s. 2003
    ..Despite these facts, an ultimate role for regional drug delivery as initial treatment of ovarian cancer will require additional trials to define how to optimize the use of this unique therapeutic strategy...
  87. ncbi Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers
    Pedro F Escobar
    Department of Gynecology/Obstetrics, Cleveland Clinic Foundation, Cleveland, OH 44195, USA
    Gynecol Oncol 92:192-6. 2004
    ..Defining a place for this three-drug program in the standard management of ovarian cancer will require the conduct of an appropriately designed randomized trial...
  88. ncbi Consolidation/maintenance chemotherapy for ovarian cancer
    Maurie Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, R35, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Curr Oncol Rep 5:454-8. 2003
    ..Whether this strategy will improve overall survival in this clinical setting remains uncertain...
  89. ncbi The role of maintenance therapy and novel taxanes in ovarian cancer
    Thomas J Herzog
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University, Herbert Irving Cancer Center, 161 Ft Washington Avenue, New York, NY 10032, USA
    Gynecol Oncol 102:218-25. 2006
    ..In addition, the role of novel taxanes, which may offer an improved therapeutic index and reduced toxicity relative to conventional therapies in this setting, is discussed...
  90. ncbi Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience
    Maurie Markman
    University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Int J Gynecol Cancer 19:223-9. 2009
    ..To assess the association between patient-disease characteristics and overall survival (OS) after second-line intraperitoneal (IP) treatment of ovarian cancer...
  91. ncbi Prolonged disease-free and treatment-free survival in platinum-resistant ovarian cancer following extended (>1 year) administration of single-agent paclitaxel: A case report and discussion of potential clinical implications
    Maurie Markman
    Department of Medical Gynecologic Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Invest 23:33-5. 2005
    ..The optimal duration of therapy for women with platinum-resistant ovarian cancer who respond to second-line treatment programs remains undefined...
  92. ncbi Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer
    Pedro F Escobar
    Department of Gynecology/Obstetrics, The Cleveland Clinic Foundation, Gynecologic Oncology Program, Cleveland, Ohio 44195, USA
    J Cancer Res Clin Oncol 129:651-4. 2003
    ..Definite, although modest, antineoplastic activity in a patient population with recurrent or advanced endometrial cancer was documented...
  93. ncbi Chemotherapeutic management of recurrent/metastatic uterine carcinosarcomas (malignant mixed mullerian tumors): time for a re-appraisal?
    Maurie Markman
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Mail Box 121, 77030, Houston, Texas 77030, USA
    J Cancer Res Clin Oncol 130:645-8. 2004
    ....
  94. ncbi Apoptotic pathways of epothilone BMS 310705
    Denise Uyar
    The Cleveland Clinic Foundation, Experimental Therapeutics Program, Taussig Cancer Center R40, 9500 Euclid Avenue, Cleveland, OH 44195, USA
    Gynecol Oncol 91:173-8. 2003
    ..Using an early passage cell culture model derived from the ascites of a patient clinically refractory to platinum/paclitaxel therapy, we evaluated the pathway of caspase-mediated apoptosis...
  95. ncbi Objective data rather than opinion in the interpretation of the legitimate goals of phase 1 oncology trials
    Maurie Markman
    University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Invest 26:11-2. 2008
  96. ncbi Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecol
    M Markman
    Cleveland Clinic Taussig Cancer Center, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA
    J Clin Oncol 19:1001-7. 2001
    ..However, the results provide direction for further clinical investigation in small-volume ovarian cancer...
  97. ncbi Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience
    Apostolia Maria Tsimberidou
    Department of Investigational Cancer Therapeutics, Unit 455, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:4423-32. 2009
    ..Thyroid cancer is the most common endocrine malignancy. The outcomes of patients with relapsed thyroid cancer treated on early-phase clinical trials have not been systematically analyzed...
  98. ncbi Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy
    K M Zanotti
    Department of Obstetrics and Gynecology, The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Gynecol Oncol 79:211-5. 2000
    ....
  99. ncbi Intraperitoneal chemotherapy in the management of malignant disease
    M Markman
    Cleveland Clinic Taussig Cancer Center R30, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA
    Expert Rev Anticancer Ther 1:142-8. 2001
    ....
  100. ncbi Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy
    K M Zanotti
    Cleveland Clinic Foundation, Cleveland, OH 44012, USA
    J Clin Oncol 19:3126-9. 2001
    ..Presently, there is no reliable way to predict which patients may be at risk for this potentially severe adverse reaction. We developed a skin-test protocol to identify patients at high risk for HR to carboplatin chemotherapy...
  101. ncbi Neurotoxicity associated with a regimen of carboplatin (AUC 5-6) and paclitaxel (175 mg/m2 over 3 h) employed in the treatment of gynecologic malignancies
    M Markman
    Department of Hematology Medical Oncology, The Cleveland Clinic Foundation, Ohio 44195, USA
    J Cancer Res Clin Oncol 127:55-8. 2001
    ..We conclude that while neurotoxicity is common following the use of this regimen, significant neurological dysfunction (> or = grade 2) is relatively infrequent...